Background: T-cell depletion causes a novel homeostasis in lymphocyte subsets in adult transplant recipients. Little is known about long-term changes in pediatric patients.

Methods: Twenty-one pediatric renal-transplant patients (mean age 11.8 years) were selected according to their initial postoperative immunosuppressive therapy: (1) baseline immunosuppression (BI) with cyclosporine, azathioprine, and steroids, n=11; and (2) BI plus polyclonal antibodies, n=10. Lymphocyte surface markers were measured in the mean 2.3 years after transplantation and analyzed between the patient groups and in regard to 46 age-matched healthy controls.

Results: The patient groups did not differ with respect to age, sex, renal function, and previous infections. Total lymphocyte counts, CD4+ T-cell numbers, and distribution of naive to memory CD4+ T cells were not different between transplant groups and controls. However, patients with postoperative T-cell depletion showed significantly lower ratios of CD4+ to CD8+ T cells, elevated CD8+ T-cell numbers, increased counts of CD8+ T cells coexpressing CD57, and higher numbers of CD8+ cells with a naive phenotype. In addition, the numbers of double-positive T cells and lymphocytes bearing both natural killer (NK) and T-cell markers were elevated in the patients with postoperative depletion. NK and B-cell counts were lower in the transplant patient groups compared with the healthy controls.

Conclusions: Pediatric transplant patients show characteristic long-term changes in lymphocyte subsets after T-cell depletion. In contrast with adult patients, these perturbations are less pronounced and predominant in the CD8+ T-cell compartment.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.TP.0000100396.81490.0CDOI Listing

Publication Analysis

Top Keywords

t-cell depletion
16
patient groups
12
cd8+ cells
12
changes lymphocyte
8
pediatric renal-transplant
8
renal-transplant patients
8
t-cell
8
lymphocyte subsets
8
long-term changes
8
t-cell numbers
8

Similar Publications

Changes in CD4+CD25HIGH T cells and TGFβ1 levels in different stages of adult-onset type 1 diabetes.

J Med Biochem

November 2024

University of Belgrade, Faculty of Medicine, University Clinical Centre of Serbia, Clinic for Endocrinology, Diabetes and Metabolic Diseases, Belgrade.

Background: Previous studies suggested an important role of impairments in T cell subsets in different stages during type 1 diabetes (T1D) development, while data regarding CD25high T cells and transforming growth factor b1 (TGFβ1), both T regulatory associated, remains controversial. We analyzed the level of (a) CD25high T cells (b) TGFβ1 in 17 first-degree relatives of patients with T1D in stage 1 (FDRs1) (GADA+, IA-2+); 34 FDRs in stage 0 (FDRs0) (GADA, IA-2); 24 recent-onset T1D in insulin-requiring state (IRS); 10 patients in clinical remission (CR); 18 healthy, unrelated controls (CTR).

Methods: T cell subsets were characterized by two-color immunofluorescence staining and flow cytometry; TGFβ1 was determined by ELISA, GADA, and IA-2 by RIA.

View Article and Find Full Text PDF

CD19-CAR T-cell therapy induces deep tissue depletion of B cells.

Ann Rheum Dis

January 2025

Department of Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany; Deutsches Zentrum Immuntherapie (DZI), Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen, Erlangen, Germany, Erlangen, Germany. Electronic address:

Objectives: CD19-targeting chimeric antigen receptor (CAR) T-cell therapy can induce long-term drug-free remission in patients with autoimmune diseases (AIDs). The efficacy of CD19-CAR T-cell therapy is presumably based on deep tissue depletion of B cells; however, such effect has not been proven in humans in vivo.

Methods: Sequential ultrasound-guided inguinal lymph node biopsies were performed at baseline and after CD19-CAR T-cell therapy in patients with AIDs.

View Article and Find Full Text PDF

functional validation of anti-CD19 chimeric antigen receptor T cells expressing lysine-specific demethylase 1 short hairpin RNA for the treatment of diffuse large B cell lymphoma.

Front Immunol

January 2025

Institute of Infection, Immunology and Tumor Microenvironment, Hubei Province Key Laboratory of Occupational Hazard Identification and Control, School of Medicine, Wuhan University of Science and Technology, Wuhan, China.

Background: Chimeric antigen receptor T (CAR-T) cell therapy is more effective in relapsed or refractory diffuse large B cell lymphoma (DLBCL) than other therapies, but a high proportion of patients relapse after CAR-T cell therapy owing to antigen escape, limited persistence of CAR-T cells, and immunosuppression in the tumor microenvironment. CAR-T cell exhaustion is a major cause of relapse. Epigenetic modifications can regulate T cell activation, maturation and depletion; they can be applied to reduce T cell depletion, improve infiltration, and promote memory phenotype formation to reduce relapse after CAR-T cell therapy.

View Article and Find Full Text PDF

We have demonstrated that the cellular protein M-Sec promotes the transmission of human T-cell leukemia virus type 1 (HTLV-1) in vitro and in vivo. Here, we show how HTLV-1 utilizes M-Sec for its efficient transmission. HTLV-1-infected CD4+ T cells expressed M-Sec at a higher level than uninfected CD4+ T cells.

View Article and Find Full Text PDF

T cells play a pivotal role in the development of autoimmune diseases. To mitigate autoimmune inflammation without inducing global immunosuppression, it is crucial to selectively eliminate autoreactive T cell clones while preserving the normal T cell repertoire. In this study, we applied cellular proximity chemistry to develop a T-cell depletion method with clonal precision.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!